202 related articles for article (PubMed ID: 24704384)
1. A single nucleotide polymorphism in SLC7A5 is associated with gastrointestinal toxicity after high-dose melphalan and autologous stem cell transplantation for multiple myeloma.
Giglia JL; White MJ; Hart AJ; Toro JJ; Freytes CO; Holt CC; Cai Y; Williams SM; Brandt SJ
Biol Blood Marrow Transplant; 2014 Jul; 20(7):1014-20. PubMed ID: 24704384
[TBL] [Abstract][Full Text] [Related]
2. A Single Nucleotide Polymorphism in
Poi MJ; Li J; Johnson JA; Cho YK; Sborov DW; Phelps MA; Hofmeister CC
Anticancer Res; 2019 Jan; 39(1):67-72. PubMed ID: 30591441
[TBL] [Abstract][Full Text] [Related]
3. Genetic polymorphisms in the amino acid transporters LAT1 and LAT2 in relation to the pharmacokinetics and side effects of melphalan.
Kühne A; Kaiser R; Schirmer M; Heider U; Muhlke S; Niere W; Overbeck T; Hohloch K; Trümper L; Sezer O; Brockmöller J
Pharmacogenet Genomics; 2007 Jul; 17(7):505-17. PubMed ID: 17558306
[TBL] [Abstract][Full Text] [Related]
4. Amifostine reduces gastro-intestinal toxicity after autologous transplantation for multiple myeloma.
Malek E; Gupta V; Creger R; Caimi P; Vatsayan A; Covut F; Bashir Q; Champlin R; Delgado R; Rondon G; Cooper B; de Lima M; Lazarus HM; Qazilbash M
Leuk Lymphoma; 2018 Aug; 59(8):1905-1912. PubMed ID: 29295650
[TBL] [Abstract][Full Text] [Related]
5. Associations of High-Dose Melphalan Pharmacokinetics and Outcomes in the Setting of a Randomized Cryotherapy Trial.
Cho YK; Sborov DW; Lamprecht M; Li J; Wang J; Hade EM; Gao Y; Tackett K; Williams N; Benson DM; Efebera YA; Rosko AE; Devine SM; Poi M; Hofmeister CC; Phelps MA
Clin Pharmacol Ther; 2017 Sep; 102(3):511-519. PubMed ID: 28160288
[TBL] [Abstract][Full Text] [Related]
6. Single versus tandem high-dose melphalan followed by autologous blood stem cell transplantation in multiple myeloma: long-term results from the phase III GMMG-HD2 trial.
Mai EK; Benner A; Bertsch U; Brossart P; Hänel A; Kunzmann V; Naumann R; Neben K; Egerer G; Ho AD; Hillengass J; Raab MS; Neubauer A; Peyn A; Ko YD; Peter N; Scheid C; Goldschmidt H
Br J Haematol; 2016 Jun; 173(5):731-41. PubMed ID: 26990892
[TBL] [Abstract][Full Text] [Related]
7. Comparison of conditioning regimen toxicities among autologous stem cell transplantation eligible multiple myeloma patients: High-dose melphalan versus high-dose melphalan and bortezomib.
Aypar E; İzzettin FV; Akı ŞZ; Sancar M; Yeğin ZA; Türköz-Sucak G
J Oncol Pharm Pract; 2018 Jun; 24(4):281-289. PubMed ID: 29284356
[TBL] [Abstract][Full Text] [Related]
8. Combination of high-dose melphalan and bortezomib as conditioning regimen for autologous peripheral blood stem cell transplantation in multiple myeloma.
Miyamoto T; Yoshimoto G; Kamimura T; Muta T; Takashima S; Ito Y; Shiratsuchi M; Choi I; Kato K; Takenaka K; Iwasaki H; Takamatsu Y; Teshima T; Akashi K
Int J Hematol; 2013 Sep; 98(3):337-45. PubMed ID: 23877150
[TBL] [Abstract][Full Text] [Related]
9. The choice of multiple myeloma induction therapy affects the frequency and severity of oral mucositis after melphalan-based autologous stem cell transplantation.
Fleming S; Harrison SJ; Blombery P; Joyce T; Stokes K; Seymour JF; Prince HM; Ritchie D
Clin Lymphoma Myeloma Leuk; 2014 Aug; 14(4):291-6. PubMed ID: 24629850
[TBL] [Abstract][Full Text] [Related]
10. High melphalan exposure is associated with improved overall survival in myeloma patients receiving high dose melphalan and autologous transplantation.
Nath CE; Trotman J; Tiley C; Presgrave P; Joshua D; Kerridge I; Kwan YL; Gurney H; McLachlan AJ; Earl JW; Nivison-Smith I; Zeng L; Shaw PJ
Br J Clin Pharmacol; 2016 Jul; 82(1):149-59. PubMed ID: 26879446
[TBL] [Abstract][Full Text] [Related]
11. A phase II, single-arm, prospective study of bendamustine plus melphalan conditioning for second autologous stem cell transplantation in de novo multiple myeloma patients through a tandem transplant strategy.
Martino M; Tripepi G; Messina G; Vincelli ID; Console G; Recchia AG; Gentile M; Molica S; Morabito F
Bone Marrow Transplant; 2016 Sep; 51(9):1197-203. PubMed ID: 27088375
[TBL] [Abstract][Full Text] [Related]
12. XRCC1-mediated DNA repair is associated with progression-free survival of multiple myeloma patients after autologous stem cell transplant.
Persaud AK; Li J; Johnson JA; Seligson N; Sborov DW; Duah E; Cho YK; Wang D; Phelps MA; Hofmeister CC; Poi MJ
Mol Carcinog; 2019 Dec; 58(12):2327-2339. PubMed ID: 31544312
[TBL] [Abstract][Full Text] [Related]
13. BEAM Conditioning Regimen Has Higher Toxicity Compared With High-Dose Melphalan for Salvage Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma.
Veeraputhiran M; Jain T; Deol A; Ayash L; Kim S; Dyson G; Bhutani D; Lum LG; Ratanatharathorn V; Uberti JP; Abidi MH
Clin Lymphoma Myeloma Leuk; 2015 Sep; 15(9):531-5. PubMed ID: 26166312
[TBL] [Abstract][Full Text] [Related]
14. A Phase I Trial of High-Dose Lenalidomide and Melphalan as Conditioning for Autologous Stem Cell Transplantation in Relapsed or Refractory Multiple Myeloma.
Mark TM; Guarneri D; Forsberg P; Rossi A; Pearse R; Perry A; Pekle K; Tegnestam L; Greenberg J; Shore T; Gergis U; Mayer S; Van Besien K; Ely S; Jayabalan D; Sherbenou D; Coleman M; Niesvizky R
Biol Blood Marrow Transplant; 2017 Jun; 23(6):930-937. PubMed ID: 28285081
[TBL] [Abstract][Full Text] [Related]
15. Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myelome (IFM).
Roussel M; Moreau P; Huynh A; Mary JY; Danho C; Caillot D; Hulin C; Fruchart C; Marit G; Pégourié B; Lenain P; Araujo C; Kolb B; Randriamalala E; Royer B; Stoppa AM; Dib M; Dorvaux V; Garderet L; Mathiot C; Avet-Loiseau H; Harousseau JL; Attal M;
Blood; 2010 Jan; 115(1):32-7. PubMed ID: 19884643
[TBL] [Abstract][Full Text] [Related]
16. Oral mucositis and outcomes of autologous hematopoietic stem-cell transplantation following high-dose melphalan conditioning for multiple myeloma.
Vera-Llonch M; Oster G; Ford CM; Lu J; Sonis S
J Support Oncol; 2007 May; 5(5):231-5. PubMed ID: 17564153
[TBL] [Abstract][Full Text] [Related]
17. Role of high-dose melphalan with autologous stem cell transplantation in multiple myeloma patients receiving botezomib-containing induction therapy.
Lee BH; Shin SH; Min CK; Yhim HY; Kwak JY; Kim JA
Int J Hematol; 2013 May; 97(5):634-9. PubMed ID: 23605366
[TBL] [Abstract][Full Text] [Related]
18. The role of high-dose melphalan and autologous stem cell transplant in the rapidly evolving era of modern multiple myeloma therapy.
Voorhees PM; Usmani SZ
Clin Adv Hematol Oncol; 2016 Sep; 14(9):719-28. PubMed ID: 27673290
[TBL] [Abstract][Full Text] [Related]
19. Dose-intensified bendamustine and melphalan (BenMel) conditioning before second autologous transplantation in myeloma patients.
Farag S; Jeker B; Bacher U; Mansouri Taleghani B; Mueller BU; Novak U; Pabst T
Hematol Oncol; 2018 Oct; 36(4):671-678. PubMed ID: 30110717
[TBL] [Abstract][Full Text] [Related]
20. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
Cavo M; Gay F; Beksac M; Pantani L; Petrucci MT; Dimopoulos MA; Dozza L; van der Holt B; Zweegman S; Oliva S; van der Velden VHJ; Zamagni E; Palumbo GA; Patriarca F; Montefusco V; Galli M; Maisnar V; Gamberi B; Hansson M; Belotti A; Pour L; Ypma P; Grasso M; Croockewit A; Ballanti S; Offidani M; Vincelli ID; Zambello R; Liberati AM; Andersen NF; Broijl A; Troia R; Pascarella A; Benevolo G; Levin MD; Bos G; Ludwig H; Aquino S; Morelli AM; Wu KL; Boersma R; Hajek R; Durian M; von dem Borne PA; Caravita di Toritto T; Zander T; Driessen C; Specchia G; Waage A; Gimsing P; Mellqvist UH; van Marwijk Kooy M; Minnema M; Mandigers C; Cafro AM; Palmas A; Carvalho S; Spencer A; Boccadoro M; Sonneveld P
Lancet Haematol; 2020 Jun; 7(6):e456-e468. PubMed ID: 32359506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
